iTechDachs
: Gestern noch ein US-Patent diesmal IO
US20190010248 - ANTI-CANCER FUSION POLYPEPTIDE Jetzt sollten noch ein oder zwei Presse-Meldungen kommen (z.B. zur AZN-Studie, Übergabe PRS-352 an Servier, FDA Freigabe zu PRS-343 Studien oder bezüglich der Verpackungseinheiten) und die Aussichten sind wieder sehr grün. Meine Meinung - KEINE Handelsempfehlung
WARUM (?) bekommt Ihr das nicht langsam mal in den Griff mit diesen Schmuddelseiten ? Wollt Ihr nicht o. könnt Ihr nicht ??? Das nimmt langsam ein Ausmaß an was nicht mehr akzeptabel ist !!! Ausserdem schadet es der Reputation von ARIVA auf das Äußerste, aber dies werden Sie ja hoffentlich selbst wissen … MfG K.H.
BOSTON,MA / ACCESSWIRE /January 19,2021 /Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, today announced that the U.
iTechDachs
: Daten zu PRS-343 und PRS-344 auf der AACR 2021
CT017 - Clinical and biomarker activity of PRS-343, a bispecific fusion protein targeting 4-1BB and HER2, from a Phase 1 study in patients with advanced solid tumors (Study PRS-343-PCS_04_16)
LB135 - Simultaneous costimulatory T-cell engagement and checkpoint inhibition by PRS-344/S095012, a PD-L1 / 4-1BB bispecific compound for tumor localized activation of the immune system
Die Tagung findet virtual vom 10-15-ten April und eine zweite Woche vom 17-21-ten Mai statt. Die klinischen Daten sind bis zum 9-ten April bzw. beim 'Late Breaker' LB135 von Servier bis zur Präsentation am 10-ten April unter Verschluss.
https://www.pieris.com/news-and-events/...of-existing-immuno-oncology "PIERIS ANNOUNCES AMENDMENT OF EXISTING IMMUNO-ONCOLOGY MULTI-TARGET COLLABORATION WITH SEAGEN, A CLINICAL TRIAL AND SUPPLY AGREEMENT TO EVALUATE CINREBAFUSP ALFA (PRS-343) IN COMBINATION WITH TUKYSA® (TUCATINIB) IN GASTRIC CANCER, AND STRATEGIC EQUITY INVESTMENT BY SEAGEN Seagen will supply Pieris with TUKYSA® to evaluate the drug in combination with cinrebafusp alfa (PRS-343) in gastric cancer Pieris' co-development option for one program from existing multi-target collaboration amended to US co-promotion option with increased royalties if exercised Seagen to purchase $13 million equity stake in Pieris common stock BOSTON, MA / ACCESSWIRE / March 25, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, today announced that Seagen has made a strategic equity investment in Pieris as part of an ongoing collaboration between the companies. In addition, the companies have entered into a clinical trial collaboration agreement to evaluate the safety and efficacy of combining Pieris' cinrebafusp alfa (PRS-343), a 4-1BB/HER2 bispecific, with Seagen's TUKYSA® (tucatinib), a small-molecule tyrosine kinase HER2 inhibitor, for the treatment of gastric cancer patients expressing lower HER2 levels (IHC2+/ISH- & IHC1+) as part of the upcoming phase 2 study to be conducted by Pieris. The companies have also amended their existing immuno-oncology collaboration agreement around joint development and commercial rights for the second of up to three products in the alliance..."
iTechDachs
: Denkbar - aber wie gesagt SGEN zahlt rund 40%
Aufschlag gegenüber dem aktuellen Kurs und Pieris hat ja einige weitere Vorteile aus der Dealergänzung: - kostenlose Kombination - Option auf Co-Promotion statt Co-Development also verbesserte Bedingungen und höhere Umsatzbeteiligungen ohne eigene Entwicklungs-/Vertriebskosten
(NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, today reported financial results for the fiscal year ended December 31, 2020 and provided an updat ...
iTechDachs
: Neue Analysten Ratings und ein heimlicher NK-Deal
Robert W. Baird auf Outperform $5 Jefferies auf Buy $12. Evercore ISI Outperform $13
Unbemerkt ist Pieris offensichtlich im März mit Glycostem eine Zusammenarbeit auf dem Gebiet der NK und CAR-NK Zelltherapien eingegangen. Glycostem hat aktuell mit der Abwerbung des TCR-Spezialisten Kai Pinkernell von Medigene als neuem CMO für ein wenig Aufsehen gesorgt und ein erstes TCR-NK Projekt gegen solide Tumore in der Pipeline.
Mal sehen wo die Reise für Pieris in diesem Kontext dank der Direkt Investments der aktuellen Partner AstraZenica und SeaGen hingehen soll.
Simultaneous costimulatory T-cell engagement and checkpoint inhibition by PRS-344/S095012, a PD-L1 / 4-1BB bispecific compound for tumor localized activation of the immune system
H.C. analysts have given a Buy rating to Pieris along with a price target of $9. Based on Friday's closing price, the firm appears to expect a big move for the stock. Whether or not that happens will again be based on how the company executes its business model this year.
Pieris focuses on building its biotech pipeline through its Anticalin technology platform for respiratory diseases. Last month the company announced that it had achieved a key milestone from AstraZeneca (NASDAQ: AZN) for the initiative of PRS-060/AZD1402 in a Phase 2a study. Specifically, Pieris achieved a $13 million milestone and AstraZeneca purchased $10 million in PIRS stock. The companies are developing a treatment for moderate-to-severe asthma.
Aside from this, Pieris has other pipeline treatments it's working on. Among them is a monotherapy, PRS-343, for HER2-expressing solid tumors. Over the weekend, the company gave an update on data presented at the American Association for Cancer Research Virtual Congress.
"The matured data from the highest dose cohort of [PRS-343] demonstrate a clear dose-dependent response that supports our recommended phase 2 dose, and the biomarker data generated across all active dose cohorts demonstrate that cinrebafusp alfa activity is 4-1BB-driven and that the drug candidate is active not only in HER2-high expressing tumors, but also HER2-low expressing tumors - a significant opportunity and unmet medical need that we are excited to pursue in our upcoming phase 2 study," said Stephen S. Yoder, President and Chief Executive Officer of Pieris.
The company also said there was clear evidence of dose-dependent synergistic anti-tumor effects of PRS-344/S095012. There was also further evidence for its tumor-localized mechanism of action. Pieris expressed an interest in moving this asset into the clinic this year.
Thread abonnieren
